2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2015

9:00AM-11:00AM: Abstract Number: 1453

Surveillance of Periodic Fever Syndromes in Canada

Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1664

Switch from Tocilizumab + Methotrexate to Tocilizumab Monotherapy. Maintenance of Response in Patients with Rheumatoid Arthritis at Low Disease Activity.

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1872

Symptomatic and Electrodiagnostic Features of Peripheral Neuropathy in Scleroderma

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1361

Synovial Macrophages Promote TGF-β Signaling but Protect Against Influx of S100A8/S100A9-Producing Cells after Intra-Articular Injections of Oxidized Low-Density Lipoproteins

Innate Immunity and Rheumatic Disease Poster II

9:00AM-11:00AM: Abstract Number: 1161

Synovial Th9 Cells Prolong Neutrophil Survival and Functionally Enhance the Infiltrating T Cells in Rheumatoid Arthritis

Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1141

Synovial Ultrasound Power Doppler Enhancement Reflects Multiple Cytokine Expression in Synovial Tissue, Distinguishing Distinct High Macrophage-Associated and Low Inflammation Profiles

Biology and Pathology of Bone and Joint Poster I: Osteoarthritis Pathogenesis

9:00AM-11:00AM: Abstract Number: 1240

Systematic Protein-Protein Interaction and Pathway Analyses in the Idiopathic Inflammatory Myopathies

Genetics, Genomics and Proteomics Poster II

9:00AM-11:00AM: Abstract Number: 1676

Systematic Review and Network Meta-Analysis of Combination Treatments in Disease Modifying Anti-Rheumatic Drug Experienced Patients with Severe Rheumatoid Arthritis: Analysis of American College of Rheumatology Criteria Scores 20, 50, and 70: An Update

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster II

9:00AM-11:00AM: Abstract Number: 1842

Systemic Lupus Erythematosus and Chikungunya Fever: Interactions during the 2014 Outbreak in Martinique

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1835

Systemic Lupus Erythematosus Does Not Increase Risk of Adverse Events in the First 6 Months after Total Knee Replacement

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

9:00AM-11:00AM: Abstract Number: 1855

Systemic Lupus Erythematosus Exosomes Contain Distinct RNA Transcripts That Differentiate Disease Activity and Modulate Cellular Function

Systemic Lupus Erythematosus - Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1902

Systemic Sclerosis and Lung Cancer Risk: Data from the Canadian Scleroderma Research Group

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

9:00AM-11:00AM: Abstract Number: 1965

T Cell Activation, Proliferation and Differentiation Markers Lack Diagnostic Accuracy for Detecting Active GCA and PMR

Vasculitis Poster II

9:00AM-11:00AM: Abstract Number: 1383

T-Cell Subset Analysis in IgG4-Related Disease and Lymphocyte-Variant Hypereosinophilic Syndrome

Miscellaneous Rheumatic and Inflammatory Diseases Poster Session II

9:00AM-11:00AM: Abstract Number: 1828

Target Modulation of a Type I Interferon Gene Signature and Pharmacokinetics of Anifrolumab in a Phase IIb Study of Patients with Moderate to Severe Systemic Lupus Erythematosus

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].